Key result
Patients with premature ASCVD had significantly lower rates of aspirin use (71.1% vs 77.4%; P<.001) and any statin use (72.9% vs 80.5%; P<.001) compared to those with nonpremature ASCVD.
Why the study?
Studies on the use of and adherence to secondary prevention therapies in patients with premature and extremely premature atherosclerotic cardiovascular disease were lacking.
Are patients with premature or extremely premature ASCVD less likely to use and adhere to aspirin and statin therapy compared to those with nonpremature ASCVD?
Population
1 248 158 adult patients with ASCVD in the US Department of Veterans Affairs health care system
Comparison
Premature or extremely premature ASCVD vs nonpremature ASCVD
Design
Multicenter cross-sectional study
Authors
Loading...
Premature ASCVD linked to lower preventive therapy adherence; hypothesis-generating for targeted adherence interventions in younger patients.
Cross-Sectional (n=1,248,158)
Yes
Are patients with premature or extremely premature ASCVD less likely to use and adhere to aspirin and statin therapy compared to those with nonpremature ASCVD?
Absolute Event Rate: 71.1% vs 77.4%
p-value: p=<.001
Patients with premature and extremely premature ASCVD have significantly lower rates of aspirin and statin use and adherence compared to those with nonpremature ASCVD, highlighting a critical gap in secondary prevention.
Mahtta et al. (2020) conducted a cross-sectional in Premature atherosclerotic cardiovascular disease (n=1,248,158). Premature ASCVD vs. Nonpremature ASCVD was evaluated on Aspirin use (p=<.001). Patients with premature ASCVD had significantly lower rates of aspirin use (71.1% vs 77.4%; P<.001) and any statin use (72.9% vs 80.5%; P<.001) compared to those with nonpremature ASCVD.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: